Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender differences in clinical features and outcomes of Fournier's gangrene among emergency department patients.

The American journal of emergency medicine·2026
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026
Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026
Same author

Team Approach: Diagnosis and Management of Pediatric Pelvic Ewing Sarcoma.

JBJS reviews·2026
Same author

Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-Up.

American journal of hematology·2026
Same author

IlluminOss photodynamic bone stabilization system: Retrospective cohort review of clinical and peri-operative imaging complications.

Clinical imaging·2026

Related Experiment Video

Updated: Apr 5, 2026

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
11:09

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry

Published on: April 17, 2018

10.7K

Sixty-minute infusion rituximab protocol allows for safe and efficient workflow.

Emily Dotson1, Brooke Crawford2, Gary Phillips3

  • 1The Ohio State Comprehensive Cancer Center-James Cancer Hospital, 460 W. 10th Ave., Columbus, OH, 43210, USA. Emily.Dotson@osumc.edu.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|August 14, 2015
PubMed
Summary

Subsequent rituximab infusions can be safely shortened to 60 minutes for non-Hodgkin

Keywords:
HypersensitivityInfusion reactionsLymphomaRituximabSixty minutes

More Related Videos

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

10.0K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Related Experiment Videos

Last Updated: Apr 5, 2026

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
11:09

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry

Published on: April 17, 2018

10.7K
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

10.0K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Rituximab is a key treatment for B cell non-Hodgkin's lymphoma (NHL).
  • Infusion reactions are common with initial rituximab doses but lessen over time.
  • A rapid infusion protocol was evaluated for safety and feasibility in an outpatient setting.

Purpose of the Study:

  • To assess the safety and feasibility of a rituximab rapid infusion protocol.
  • To evaluate the efficacy of shortened infusion times for subsequent rituximab doses.
  • To determine the impact on patient safety and resource utilization.

Main Methods:

  • Prospective study of 50 B cell NHL patients receiving their second rituximab dose.
  • Rapid infusion protocol: 60 minutes without steroid premedication.
  • Comparison of time savings and infusion-related reactions against standard protocol.

Main Results:

  • No infusion-related reactions observed during rapid rituximab infusions (0%).
  • Mean infusion time was 62.4 minutes, saving 94.2 minutes compared to standard.
  • 100% nurse satisfaction reported with the rapid infusion protocol.

Conclusions:

  • Subsequent rituximab infusions are safe when administered over 60 minutes without steroids.
  • Rapid infusions reduce resource utilization and enhance nursing satisfaction in experienced centers.
  • Appropriate patient screening is crucial for the successful implementation of rapid rituximab infusions.